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a b s t r a c t
The APOBEC3 (A3) deaminases are retrovirus restriction factors that were proposed as inhibitory
components of HIV-1 gene therapy vectors. However, A3 mutational activity may induce undesired
genomic damage and enable HIV-1 to evade drugs and immune responses. Here, we show that A3A
protein from Colobus guereza (colA3A) can restrict HIV-1 replication in producer cells in a deaminase-
independent manner without inducing DNA damage. Neither HIV-1 reverse transcription nor integration
were signiﬁcantly affected by colA3A, but capsid protein synthesis was inhibited. The determinants for
colA3A restriction mapped to the N-terminal region. These properties extend to A3A from mandrills and
De Brazza's monkeys. Surprisingly, truncated colA3A proteins expressing only the N-terminal 100 amino
acids effectively exclude critical catalytic regions but retained potent cellular restriction activity. These
highlight a unique mechanism of cellular HIV-1 restriction by several Old World monkey A3A proteins
that may be exploited for functional HIV-1 cure strategies.
& 2014 Published by Elsevier Inc.
Introduction
Humans express several innate host factors that restrict the
replication of lentiviruses such as human immunodeﬁciency virus
type 1(HIV-1). These innate restriction factors include the apoli-
poprotein B mRNA-editing enzyme catalytic peptide 3 (APOBEC3;
A3) proteins, bone marrow stromal antigen 2 (BST-2, also known
as CD317, HM1.24 or tetherin), and tripartite motif (TRIM) proteins
(Neil et al., 2008; Sheehy et al., 2002; Stremlau et al., 2004; Van
Damme et al., 2008). These restriction factors have been the focus
of intense study during the past decade due to their translational
potential as novel drug targets and as antiviral components of
gene therapy conﬁgurations for functional HIV-1 cure strategies
(Ao et al., 2011; Bushman, 2002; Voit et al., 2013).
The A3 family of proteins includes seven members (A3A, A3B,
A3C, A3D, A3F, A3G, and A3H) whose genes are tandemly arranged
on human chromosome 22 and rhesus macaque chromosome 10
(Jarmuz et al., 2002; Schmitt et al., 2011). The APOBEC3 proteins are
cytidine deaminases that also include activation-induced cytidine
deaminase (AID), APOBEC1, APOBEC2, and APOBEC4. All A3 proteins
have a canonical zinc-coordinating deaminase domain (H-x-E-x 23–28-
PC-x2–4-C) that converts cytidine to uracil (C-to-U) in DNA targets
(MacGinnitie et al., 1995). The seven A3 proteins can be further
divided into those with a single deaminase domain (A3A, A3C, and
A3H) and with two deaminase domains (A3B, A3D, A3G, A3F)
(Desimmie et al., 2013; Kitamura et al., 2011; Refsland and Harris,
2013). The anti-HIV-1 activity of the human A3G (hA3G) was
initially discovered during the characterization of wild type HIV-1
and HIV-1Δvif viruses produced from permissive (non-A3G
expressing) and non-permissive (A3G expressing) cells (Sheehy
et al., 2002). A3G has been shown to restrict HIV-1Δvif by both
deaminase-dependent and independent mechanisms. Restriction
requires its incorporation into the viral nucleocapsid during virion
egress from producer cells. The Vif protein counteracts A3G
incorporation by acting as an adapter that interacts with both
A3G and members of the Cullin 5 E3 ligase complex (Mehle et al.,
2004, 2006; Xiao et al., 2006). This results in the ubiquitination
both Vif and the A3G and subsequent degradation by the protea-
some, thus limiting the amount of A3G that could be incorporated
into virions (Conticello et al., 2003; Iwatani et al., 2007; Liu et al.,
2004; Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2002,
2003;Yu et al., 2003). The mechanism for how hA3G inhibits
HIV-1Δvif replication is controversial, with different groups pre-
ferring either a deaminase-dependent or deaminase-independent
mechanism (Santiago and Greene, 2007). When A3G containing
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viruses infect a target cell, the incorporated A3G causes cytidine
deamination of minus strand viral DNA during reverse transcrip-
tion (Chelico et al., 2006; Yu et al., 2004). The end result of the
action of this cytidine deaminase is G-to-A mutations in the sense
strand of the viral DNA incorporated into the host chromosome.
Deaminase-independent mechanisms of restriction involve inhibi-
tion of reverse transcription by preventing: (a) tRNA annealing to
the viral RNA; (b) DNA elongation; and (c) strand transfer (Guo et
al., 2006, 2007; Iwatani et al., 2007; Li et al., 2007; Yang et al.,
2007). Another report showed that A3G and A3F can interact with
integrase and prevent integration (Luo et al., 2007).
Previous studies have shown that hA3A does not restrict the
replication of HIV-1Δvif in CD4þ T cells but restricts HIV-1Δvif in
macrophages (Berger et al., 2011; Bishop et al., 2004; Koning et al.,
2011; Thielen et al., 2010). The inability of hA3A to restrict HIV-
1Δvif has been linked to its poor incorporation into the nucleo-
capsid complex during maturation. Targeting hA3A to the nucleo-
protein complex by either fusion to the N-terminal domain of A3G
or fusion to Vpr results in enhanced incorporation and restriction
activity (Aguiar et al., 2008; Goila-Gaur et al., 2007). Human A3A
has been shown to inhibit retrotransposition, to induce DNA
damage responses, and inhibit the replication of adeno-associated
viruses and autonomously replicating parvoviruses (Bogerd et al.,
2006; Bulliard et al., 2011; Chen et al., 2006; Landry et al., 2011;
Muckenfuss et al., 2006; Narvaiza et al., 2009). Finally, hA3A can
restrict HTLV-I and can cause G-to-A hypermutation of human
papillomavirus, herpes simplex 1 and Epstein Barr virus genomes
(Ooms et al., 2012; Suspène et al., 2011b; Vartanian et al., 2008).
Until recently, all APOBEC3 proteins shown to restrict HIV-
1Δvif replication do so in the target cell, not the producer cell. In
an effort to understand APOBEC3-mediated lentivirus restriction
from an evolutionary perspective, we examined the virus restric-
tion activity of several Old World monkey A3A proteins and
showed that the A3A protein from the black and white colobus
monkey (mantled guereza; Colobus guereza; colA3A) potently
inhibited not only HIV-1Δvif replication but also wild-type HIV-
1 in producer cells (Schmitt et al., 2013). In this report, we extend
these ﬁndings by showing that the N-terminal domain of colA3A is
critical for cellular HIV-1 restriction, that the A3A proteins from
other OWM can also restrict the replication of wild type HIV-1 and
that colA3A affects HIV-1 replication at a post-integration step.
The results could have important implications in designing gene-
therapy approaches using on the unique HIV-1 restriction proper-
ties of colA3A, mndA3A or debA3A.
Results
Cells expressing HA–colA3A inhibit HIV-1 production
TZM-bl cells were transfected with a vector expressing
HA–colA3A and selected for G-418 resistance for 2 weeks. The
resulting G-418 resistant cells were analyzed for the expression of
HA–colA3A by immunoprecipitation using an antibody against
the HA-tag. The immunoprecipitation analysis revealed that the
TZM-bl cells transfected with the vector expressing HA–colA3A
expressed HA–colA3A while the parental TZM-bl cell line was
negative for HA–colA3A expression (Fig. 1A). We used these HA–
colA3A expressing cells to determine if they would restrict the
replication of HIV-1. TZM-bl cells expressing HA-colA3A were
inoculated with HIV-1 at an MOI of 1.0 and at 48 h post-inocula-
tion, the culture supernatants were assessed for Gag p24 release
(Fig. 1B). The results indicate that HIV-1 production was signiﬁ-
cantly inhibited in TZM-bl cells expressing HA–colA3A, analogous
to our previous co-transfection studies (Schmitt et al., 2013).
ColA3A does not affect HIV-1 reverse transcription
We determined if colA3A inhibited reverse transcription of
HIV-1. For these experiments, 293 cells were transfected with
either the empty pcDNA3.1(þ) vector or one expressing HA–
colA3A. At 24 h post-transfection, cultures were inoculated with
VSV-G pseudotyped envelope glycoprotein defective HIV-1 (HIV-
1ΔE-/VSV-G) and incubated for 0 or 24 h. Total DNA was isolated,
RNase A-treated and used in PCR reactions to detect late (U5-gag)
reverse transcription products. While the results indicate that the
nucleoside reverse transcriptase inhibitor AZT inhibited U5-gag
products, the levels of late reverse transcription products were not
statistically different between cells transfected with the empty
vector or one expressing HA–colA3A (Fig. 2). These ﬁndings
indicate that colA3A does not inhibit HIV-1 replication at the step
of reverse transcription.
ColA3A does not affect HIV-1 integration
One of the consequences of inefﬁcient integration is an increase
in the number of 2-LTR circles (Butler et al., 2001). 293 cells were
transfected with a vector expressing colA3A for 24 h followed by
inoculation of cultures HIV-1ΔE/VSV-G. The cells were incubated
for an additional 48 h and real time DNA PCR used to quantify the
levels of 2-LTR circles (Butler et al., 2001). Controls for 2-LTR circle
formation included 293 cells inoculated with HIV-1ΔE/VSV-G in
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Fig. 1. TZM-bl cells expressing HA–colA3A restrict HIV-1 replication. Panel A. TZM-
bl cells were transfected with pcDNA3.1(þ) expressing HA–colA3A and selected
with G-418 for two weeks. These cultures were starved for methionine/cysteine
and then radiolabeled with 200 μCi of 35S-methionine/cysteine for 6 h. Cell lysates
were prepared and HA-containing proteins immunoprecipitated using an anti-HA
antibody. The proteins were separated by SDS-PAGE (12% gel) and visualized by
standard autoradiography techniques. Lane 1. HA-containing proteins immunopre-
cipitated from TZM-bl–colA3A cells using a control rabbit antibody. Lane 2. HA-
containing proteins immunoprecipitated from TZM-bl–colA3A cells using a rabbit
anti-HA antibody. Panel B. TZM-bl cells expressing HA–colA3A cells restrict HIV-1
replication. TZM-bl and TZM-bl cells expressing HA–colA3A in 6-well plates were
inoculated with 103 TCID50 of HIV-1 or HIV-1Δvif for 4 h. The inoculum was
removed, washed three times and fresh medium added to cultures. At 48 h, the
culture medium was harvested and virion infectivity measured using TZM-bl cells.
The experiments were performed at least three times. Shown is the mean
percentage virion infectivity of virus inoculated onto TZM-bl cells normalized to
100%. Statistical differences with the wild-type control were evaluated using a two-
tailed Student's t-test, with po0.05 (Δ) considered signiﬁcant.
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the presence or absence of 20 nM raltegravir. The results of real
time DNA PCR indicated over a 10-fold increase in the number of
2-LTR circles in DNA samples from 293 cultures transfected with
the empty vector pcDNA3.1(þ) and inoculated with HIV-1ΔE-/
VSV-G in the presence of 20 nM raltegravir versus 293 cultures
transfected with pcDNA3.1(þ) and inoculated with HIV-1ΔE/VSV-
G in the absence of 20 nM raltegravir (Fig. 3A). The levels of 2-LTR
circles detected in cultures transfected with the plasmid expres-
sing HA–colA3A and inoculated with HIV-1ΔE/VSV-G were similar
to cultures transfected with the empty pcDNA3.1(þ) vector and
inoculated with HIV-1ΔE/VSV-G.
We also used real time DNA PCR to quantify the levels of
integration events using established procedures for detecting Alu-
gag sequences (Butler et al., 2001). The results of real time DNA
PCR indicated a 100-fold decrease in the levels of Alu-gag
sequences detected in DNA samples from 293 cultures transfected
with the empty vector pcDNA3.1(þ) followed by inoculation with
HIV-1ΔE/VSV-G in the presence of 20 nM raltegravir versus 293
cultures transfected with pcDNA3.1(þ) and inoculated with HIV-
1ΔE/VSV-G in the absence of raltegravir (Fig. 3B). The levels of
Alu-gag sequences detected in the 293 cells transfected with a
plasmid expressing colA3A and inoculated with HIV-1ΔE/VSV-G
were not statistically different from cultures transfected with
pcDNA3.1(þ) and inoculated with HIV-1ΔE/VSV-G. The results
of the 2-LTR circles and Alu-gag assays indicate that colA3A did not
signiﬁcantly affect integration.
The N-terminal region of the colA3A contains the critical
determinants for restricting HIV-1 production
We previously showed that hA3A did not restrict HIV-1Δvif
while colA3A restricted both HIV-1 and HIV-1Δvif (Schmitt et al.,
2011, 2013). Chimeric colobus/human A3A proteins were con-
structed to deﬁne the determinants of colA3A restriction (Fig. 4).
All human/colobus chimeric proteins were expressed well in 293
cells (Fig. 5A). The ﬁrst two chimeric colobus/human A3A chimeras
tested was col1–100hA3A, in which the ﬁrst 100 amino acids of
colA3A were fused to the C-terminal region of hA3A and h1–100
colA3A, in which with the ﬁrst 100 amino acids of hA3A fused to
the C-terminal region of colA3A. The results of the restriction
assays indicated that col1–100hA3A but not h1–100colA3A restricted
HIV-1 infectious virus production as measured using the TZM.bl
assay (Fig. 5B and C). We also examined chimeric proteins with
the N-terminal 75, and 50 amino acids of colA3A fused to hA3A
(col1–75hA3A, col1–50hA3A). Restriction assays showed that
col1–75hA3A, col1–50hA3A and col1–33hA3A restricted HIV-1 at
approximately 5%, 10%, and 15% of the empty vector control,
respectively. We also examined the levels of p24 release and
obtained similar results (Fig. 5C). However, if we normalized
infectious titer to p24 levels we observed no effect on HIV-1
virion infectivity (data not shown). These results indicate that the
colA3A N-terminal domain harbor the critical determinants for
HIV-1 restriction.
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Fig. 2. ColA3A does not affect reverse transcription of HIV-1. Panel A. 293 cells
were transfected with either empty vector pcDNA3.1(þ) or one expressing HA–
colA3A. At 24 h post-transfection cells inoculated with pseudotyped HIV-1 (HIV-
1ΔE/VSV-G). At 24 h post-inoculation, the cells were washed three times, total DNA
extracted, and the levels of U5-gag transcripts quantiﬁed using real time DNA PCR
as described in the text. The values obtained are presented as copies/μg. The
experiments were performed at least four times and statistical differences with the
untagged rhA3A control were evaluated using a two-tailed Student's t-test, with
po0.05 (Δ) considered signiﬁcant. Shown is the mean percentage virion infectivity
with the empty plasmid control normalized to 100%.
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Fig. 3. ColA3A does not affect viral integration. 293 cells were transfected with
either empty vector of one expressing colA3A. At 24 h, cells were inoculated with
pseudotyped NL4-3-DE-EGFP/VSV virus as described in the “Materials and
methods” section. Cells were harvested at 48 h post-inoculation and total DNA
extracted and using in real time DNA PCR to quantify levels of 2-LTR circles (Panel
A) or Alu-gag products (Panel B). An additional negative control included treatment
of transfected/infected cells with 20 mM raltegravir for 2 h prior to inoculation of
cultures with pseudotyped virus.
M. Katuwal et al. / Virology 468-470 (2014) 532–544534
ColA3A inhibits HIV-1 virus protein synthesis in producer cells
Since colA3A does not inhibit HIV-1 reverse transcription and
integration, but had a reproducible inhibitory impact on virion
release, we next evaluated the levels of intracellular Gag p24
levels. Infected cells were lysed and p24 levels quantiﬁed. As
shown in Fig. 5D, the levels of p24 in the cell lysates were
dramatically reduced in colA3A-transfected, but not hA3A-trans-
fected, producer cells. We further mapped the inhibition of cellular
p24 synthesis of colA3A to the N-terminal domain (Fig. 5D). The
levels of p24 in the cell lysates paralleled the levels of p24 release
(compare Fig. 5C and D). Thus, colA3A inhibits virus protein
production in producer cells.
Other Old World monkey A3A proteins restrict HIV-1 replication by a
mechanism similar to colA3A
As colA3A1–100hA3A but not h1–100col A3A had opposite effects
on restricting HIV-1, we examined the N-terminal sequences of the
several OWM to determine if the A3A sequences from other OWM
were similar to colA3A (Fig. 6). Our analysis indicates that the A3A
proteins from Mandrillus sphinx (mndA3A) and Cercopithecus
neglectus (debA3A) had an AC-loop1 region that was similar to
colA3A. We generated constructs in pcDNA3.1(þ) vector as we
previously described for HA–rhA3A, and HA–colA3A (Schmitt et
al., 2013). Both mndA3A and debA3A were expressed well in 293
cells (Fig. 7A). 293 cells were transfected with vectors expressing
either hA3A, rhA3A, colA3A, debA3A, or mndA3A and plasmids
with the genomes of HIV-1. The culture supernatants were
harvested and cell lysates prepared at 48 h and assayed for p24
content and infectivity using TZM-bl cells. The experiment was
repeated at least four times. As shown in Fig. 7B, colA3A, debA3A
and mndA3A restricted HIV-1 while hA3A and rhA3A did not
restrict HIV-1 replication. Similar to colA3A, the levels of p24 in
the culture supernatants and cell lysates prepared from producer
cells were signiﬁcantly reduced compared to empty vector con-
trols or cells transfected with vectors expressing hA3A (Fig. 7C
and D).
To determine if restriction by these select OWM A3A proteins is
speciﬁc to lentiviruses, we tested if A3A can inhibit a gammare-
trovirus, Friend Murine Leukemia virus (F-MuLV). We speciﬁcally
evaluated the mndA3A, as it was the consistently most potently
restricted virus HIV-1. An F-MuLV infectious molecular clone was
co-transfected with the empty vector, or vectors expressing hA3A,
rhA3A, mndA3A, or hA3G. The A3A proteins were expressed well
in transfected cells (Fig. 7E). Consistent with other previous
studies (Santiago et al., 2008; Takeda et al., 2008), hA3G potently
restricted F-MuLV replication (Fig. 7F). Moreover, as expected from
a recent study (Stavrou et al., 2014), hA3A partially inhibited F-
MuLV replication. Interestingly, rhA3A and mndA3A did not
restrict Fr-MuLV replication (Fig. 7F). These ﬁndings demonstrate
not all retroviruses are susceptible to mndA3A restriction.
Truncated colA3A, mndA3A and debA3A proteins can restrict HIV-1
As the above results indicated that the ﬁrst 100 amino acids of
colA3A contained the determinants of HIV-1 restriction, we
determined if truncated colA3A, mndA3A and debA3A proteins
could also restrict HIV-1 replication. Truncated versions of colA3A
were constructed that expressed the N-terminal 100 amino acids
(colA3A1–100, mndA3A1–100, debA3A1–100). We next examined the
intracellular localization of HA–colA3A and HA–colA3A1–100 in
Fig. 4. Sequence of colA3A, hA3A and different chimeric proteins analyzed in this study. For each chimeric protein, the hA3A sequences are bolded and the colA3A sequences
not bolded.
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transfected 293 cells using immunoﬂuorescence and confocal
microscopy to determine if the truncated A3A was localized in
different compartments than the unmodiﬁed A3A protein. 293
cells were transfected with the empty vector or vectors expressing
either mndA3A or mndA3A1–100. At 48 h cells were examined for
the intracellular localization of the A3A proteins using an anti-HA
antibody. The results indicate that similar to HA–colA3A,
HA–colA3A1–100 was also localized in both the cytoplasmic and
nuclear compartments of the cell (Fig. 8A–F). We next examined
the restriction activity of these A3A proteins. 293 cells were
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Fig. 5. Chimeric colobus/human A3A proteins revealed that the N-terminal region of colA3A has the determinants to restrict HIV-1. Panel A. Expression of the wild type and
chimeric A3 proteins. 293 cultures were transfected with vectors expressing each wild type and chimeric protein. At 48 h, cells were starved and radiolabeled with 35S-
methionine/cysteine for 6 h. The mediumwas removed, cell lysates prepared in 1XRIPA buffer and HA-tagged proteins immunoprecipitated with an antibody against the HA-
tag and protein A Sepharose. The proteins were resolved using SDS-PAGE and visualized by standard radiographic techniques. The lanes correspond to the vector used to
transfect the 293 cells. Panels B-D. 293 cells were transfected with plasmids expressing hA3A, colA3A, col1–100hA3A, h1–100colA3A, col1–75hA3A, col1–50hA3A, or col1–33hA3A
the plasmid with the HIV-1 genome. At 48 h, the culture supernatants were collected and assayed for infectious virus using TZM-bl as an indicator cell line p24 levels in the
culture supernatants and cell lysates. Panel B. The level of infectious virus in the culture supernatants from transfected cells using TZM.bl assays. Panel C. Levels of p24
antigen in the culture supernatants from transfected cells using commercially available p24 antigen capture kits. Panel D. Levels of p24 antigen in the cell lysates from
transfected cells using commercially available p24 antigen capture kits. The experiments in Panels B–D were performed at least three times and statistical differences with
the pcDNA3.1(þ) empty vector/HIV-1 control evaluated using a two-tailed Student's t-test, with po0.05 (Δ) considered signiﬁcant.
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transfected with plasmids with the HIV-1 genome and 48 h later
the culture medium was harvested. The levels of p24 Gag were
measured and levels of infectious virus determined using TZM-bl
assays. Our results show that the truncated A3A proteins were just
as effective as the full length colA3A at restricting infectious HIV-
1production (Fig. 9A and B). The truncated colA3A, debA3A, and
mndA3A also inhibited HIV-1 p24 synthesis in producer cells and
release into the culture supernatants, similar to the full length
counterparts (Fig. 9C and D). As negative controls, rhA3A did not
restrict HIV-1 in these experiments.
A chimeric hA3A containing the AC Loop1 region of mndA3A restricts
HIV-1
Previously we reported that substitution of the hA3A AC loop
1 region with rhA3A restricted the replication of HIV-1Δvif. We
were very interested in the mndA3A as it restricted HIV-1 to a
higher level than either colA3A and debA3A. We constructed and
expressed a chimeric hA3A/mndA3A in which the AC Loop1 region
of hA3A (27GI-GRHK32) was exchanged for AC Loop 1 region of
mndA3A (27KLWVSGQRE35) (Fig. 6). This chimera, designated as
mnd25–34hA3A was used in restriction assays along with hA3A,
mndA3A, colA3A and an empty vector control. The results of the
restriction assays revealed that the mnd25–34hA3A was nearly as
effective at mndA3A at restricting HIV-1 while hA3A did not
restrict HIV-1 (Fig. 10A–C). These results indicate that the AC
Loop1 region of mndA3A was critical to its restriction properties.
Induction of a DNA damage response by full length colA3A but not
truncated colA3A1–100
It was previously shown that hA3A could induce a DNA damage
response resulting in the phosphorylation of H2AX to γH2AX
(Landry et al., 2011). It remains unknown whether this property is
conserved in colA3A. We therefore determined if colA3A induced a
DNA damage response in 293 cells. Controls for induction of
γH2AX were cells incubated with 20 μM etoposide (Tanaka et al.,
2007). Cells were transfected with the empty vector pcDNA3.1(þ)
or vectors expressing HA–hA3A or HA–colA3A for 36 h. At this
point the cells were either left untreated or treated with 20 μM
etoposide for 12 h. At 48 h the cells were lysed and examined for
γH2AX expression by immunoblots using a γH2AX speciﬁc anti-
body. Background levels of γH2AX expression were observed 293
cells or 293 cells transfected with the empty vector while cultures
treated with 20 μM etoposide clearly induced the expression of
γH2AX and its monoubiquitinated variant (Fig. 11). Transfection of
293 cells with vectors expressing hA3A showed low levels of
γH2AX expression and its monoubiquitinated variant compared to
treatment with 20 μM etoposide while cells transfected with the
vector expressing colA3A showed just above background levels of
γH2AX expression (Fig. 11). These data indicate that hA3A and
perhaps colA3A induced γH2AX (albeit a small response compared
to etoposide) when exogenously expressed from strong promoters.
Since HA–colA3A1–100 was also effective at restricting HIV-1
and that the determinants required for A3A to induce H2AX are
largely unknown, we determined if this truncated proteins would
induce γH2AX. 293 cells were transfected with the empty control
vector or vectors expressing HA–hA3A, HA–colA3A, and HA–
colA3A1–100 for 48 h. Cells were stained for the presence of γH2AX
by immunoﬂuorescence using a γH2AX-speciﬁc antibody. Expres-
sion of γH2AX was not detected in 293 transfected with the empty
vector but low levels of γH2AX could be detected in cells
transfected with the vector expressing hA3A when compared with
cells treated with 20 μM etoposide (Fig. 11). However, 293 cells
transfected with vectors expressing HA–colA3A1–100 for 48 h did
not induce γH2AX expression. Taken together, these data indicate
that HA–colA3A1–100 did not induce a DNA damage response when
exogenously expressed.
Discussion
Deciphering the mechanism of colA3A restriction could be
instrumental in designing novel antiviral strategies against HIV-
1. We show here that TZM-bl cells expressing colA3A (TZM-bl–
colA3A) inoculated with either HIV-1 or HIV-1Δvif viruses reca-
pitulated the observed virus restriction using plasmids, thus ruling
out that the observed colA3A restriction was an artifact of
transfection process. Our studies also showed that colA3A does
not target the reverse transcription or integration steps of the
virus replication cycle and that cytidine deamination is not
involved. These data provide additional support that colA3A
restricts virus replication by a novel deaminase-independent
mechanism not previously described for any APOBEC3 protein.
In a previous study, the binding efﬁciency of hA3A to a 40
nucleotide ssRNA was reported to be approximately 3-fold higher
than for the corresponding 40 nt ssDNA (Byeon et al., 2013). More
recently, it was shown that hA3A binds single stranded RNA
(ssRNA) but no deamination of ssRNA occurs (Mitra et al., 2014).
Thus, it is possible that colA3A with its different AC-loop-1 region
may interact more strongly with ssRNA than ssDNA and may
inhibit virus replication by interfering in transcription and/or
translation. We previously used a chimeric protein approach to
show that substitution of AC loop1 of hA3A with that of rhA3A
restored the ability to hA3A to restrict HIV-1Δvif (Schmitt et al.,
2013). We hypothesized that the three amino acid insertion in AC
loop 1 of rhA3A could result in a AC-Loop1 with a greater
molecular surface compared to hA3A. Due to its predicted sol-
vent-accessibility, this additional molecular surface may be an
important region for protein–protein interactions (Schmitt et al.,
2013). Using a similar approach we found that determinants
within the N-terminal domain (i.e. the ﬁrst 100 amino acids)
which includes the AC Loop-1 region of colA3A are likely involved
in the restriction of HIV-1 as chimeric proteins col1–100hA3A
restricted at levels similar to full length A3A while col1–75hA3A,
col1–50hA3A, and col1–33hA3A showed a gradual reduction in the
Fig. 6. The N-terminal amino acid sequence of the A3A proteins from several Old World monkey species. The box is the predicted AC-loop 1 region from each A3A showing
that the AC loop 1 region of Cercopihtecus neglectus (De Brazza's monkey) and Mandrillus sphinx (mandrill) most closely resemble Colobus guereza (black and white colobus
monkey).
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Fig. 7. The A3A proteins from other Old World monkeys also restrict HIV-1 by a similar mechanism. Panel A. Expression of the wild type and chimeric A3 proteins. 293 cultures were
transfected with the empty pcDNA3.1(þ) vector or those expressing hA3A, rhA3A colA3A, mndA3A, or debA3A. At 48 h, cells were starved and radiolabeled with 35S-methionine/
cysteine for 6 h. Themediumwas removed, cell lysates prepared in 1XRIPA buffer and HA-tagged proteins immunoprecipitated with a rabbit antibody against the HA-tag and protein A
Sepharose. The proteins were resolved using SDS-PAGE and visualized by standard radiographic techniques. The lanes correspond to the vector used to transfect the 293 cells. Panels B–
D. 293 cells were transfected with pcDNA3.1(þ)empty vector or vectors expressing either hA3A, colA3A, rhA3A, mndA3A, or debA3A and the vector with the HIV-1 genome. At 48 h,
the culture supernatants were collected and assayed for infectious virus using TZM-bl as an indicator cell line or p24 levels in the culture supernatant and in cell lysates. Panel B. The
level of infectious virus in the culture supernatants from transfected cells using TZM.bl assays. Panel C. Levels of p24 antigen in the culture supernatants from transfected cells using
commercially available p24 antigen capture kits. Panel D. Levels of p24 antigen in the cell lysates from transfected cells using commercially available p24 antigen capture kits. The
experiments in panels B–D were performed at least four times and statistical differences with the pcDNA3.1(þ)/HIV-1 control evaluated using a two-tailed Student's t-test, with
po0.05 (Δ) considered signiﬁcant. Panels E and F. F-MuLV is not sensitive to mndA3A. The pLRB302 F-MuLV infectious molecular clone were co-transfected with A3A constructs into
293T cells. A3A expression were evaluated by western blot and infectious titers were quantiﬁed using a focal infectivity assay in Mus dunni cells. The experiments in Panels B–F were
performed at least twice and statistical differences with the pcDNA3.1(þ)/HIV-1 control evaluated using a two-tailed Student's t-test, with po0.05 (Δ) considered signiﬁcant.
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level of restriction although they were still at statistically signiﬁ-
cant levels.
Analysis of the AC-Loop-1 regions from hA3A and colA3A
revealed signiﬁcant variability in N-terminal domain sequences.
We analyzed the A3A sequences of other OWM with AC Loop1
(25KPWVSGQRE33) sequences similar to colA3A. We found that the
A3A proteins from both C. neglectus (debA3A; 25KPWVSGQRE33)
and M. sphinx (mndA3A; 25KLWVSGQHE33) were identical or
nearly identical to colA3A in this region. Similar to colA3A, we
observed that debA3A and mndA3A restricted HIV-1 with
mndA3A being slightly more restrictive than colA3A and debA3A.
The restriction of HIV-1 by these A3A proteins appears to be
speciﬁc since mndA3A did not restrict Friend MuLV, gammaretro-
virus. The Old World monkeys (Family Cercopithecidae) are com-
posed of two subfamilies (Cercopithecinae and Colobinae). The
Cercopithecinae are further classiﬁed into two tribes, the Cerco-
pithecini, and the Papionini. The Colobiniae are generally classiﬁed
into the African and Asian colobines. Our ﬁndings indicate that
restriction of wild type HIV-1 by A3A is represented by species in
two tribes of the Cercopithecinae (Cercopithecini, debA3A; and
Papionini, mndA3A) and by the African group of the Colobinae.
These results also reinforce our previous ﬁndings that the
sequence of the AC Loop1 region is critical for restriction of wild
type HIV-1 by OWM A3A proteins. Notably, while these three
monkey species express an A3A that restricts HIV-1, all three
monkeys are known to harbor endemic SIV infections (SIVcol,
SIVmnd, and SIVdeb) (Courgnaud et al., 2001; Souquiere et al.,
2001; Bibollet-Ruche et al., 2004). It will be of interest to
determine if the Vif protein from these SIV strains counteract
the corresponding A3A proteins to allow for productive SIV
replication. Moreover, it will be of interest to determine if other
OWM species also express A3A proteins that restrict HIV-1 in
producer cells and if the hA3A protein can potently inhibit HIV-1
with a few amino acid substitutions mimicking the colA3A in the
AC-loop 1 region.
A major difference between the A3A proteins and those of the
Old World monkeys is a 3 amino acid deletion from the AC Loop1
region in the hominids. Previously, we showed that deletion of
these amino acids from the rhA3A abolished its ability to restrict
SHIVΔvif (Schmitt et al., 2011). Subsequently, we showed that
substitution of the hA3A AC Loop1 region with the same region of
rhA3A endowed this chimeric hA3A with the ability to restrict
HIV-1Δvif (Schmitt et al., 2013). As our chimeric human/colobus
protein data indicated that the determinants of restriction were
associated with the N-terminal domain, we determined if the AC
loop1 region was once again critical to this restriction. As the
mndA3A consistently restricted HIV-1 to a higher level of the
three Old World monkey A3A proteins tested, we constructed an
hA3A contained the mndA3A AC loop 1 region. Our results
indicated that the level of virus restriction by mnd25–34hA3A
was similar to mndA3A indicating that this region was critical for
restriction of HIV-1. Recently, it was shown that this region in
hA3A was important in controlling substrate speciﬁcty (Logue et
al., 2014). These investigators showed that a chimeric hA3A/A3G
protein with the AC Loop 1 region (referred to as recognition loop
1or RL1) of hA3G was more ﬂexible with respect to the nucleotide
50 to the deaminated C, deaminating AC, CC, and GC with
increased frequency. Unfortunately these investigators did not
examine the virus restriction of this chimeric hA3A/A3G protein.
Nevertheless, these results further highlight the importance of
this region in the biological function of this single deaminase
domain protein.
As our data showed that the N-terminal region of colA3A had
the determinants for HIV-1 restriction and that mndA3A and
debA3A also restricted HIV-1, we determined if truncation of these
A3A proteins retained the ability to restrict HIV-1. Our data clearly
indicated that all three truncated A3A proteins (colA3A1–100,
mndA3A1–100, and debA3A1–100) restricted HIV-1. Similar to the
full length A3A proteins, the restriction involved reduced Gag
expression in the producer cells. These results indicate that the
HA-colA3A1-100HA-colA3ApcDNA3.1(+)
Anti-HA
DAPI
Fig. 8. HA–colA3A1–100 is expressed in both the cytoplasm and nucleus. 293 cells were transfected with either the empty vector, HA–colA3A or HA–colA3A1–100. At 48 h, the
cells were washed, ﬁxed and stained using an antibody against the HA-tag conjugated with Alexa488 and counterstained with DAPI to visualized the nuclei. The stained cells
were visualized using a Leica TCS SPE laser scanning confocal microscope using ﬁlters to visualize the DAPI (Panels A–C) visualize the Alexa488 (Panels D–F). Shown are
micrographs of cells transfected with empty pcDNA3.1(þ) vector (Panels A and D), HA–colA3A (Panels B and E), and HA–colA3A1–100 (Panels C and F).
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canonical cytidine deamination domain was not essential for
restriction and represents the ﬁrst demonstration that a single
deaminase A3 protein could be signiﬁcantly truncated (i.e., 50%)
without loss of restriction activity. These results further support
the idea that some A3 proteins evolved the capacity to inhibit
lentiviruses in a deaminase-independent manner.
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Fig. 9. Truncated colA3A, mndA3A, and debA3A proteins restrict wild type HIV-1. Panel A. Expression of the wild type and chimeric A3 proteins. 293 cultures were
transfected with the empty pcDNA3.1(þ) vector or vectors expressing colA3A, mndA3A, debA3A, colA3A1–100, mndA3A1–100, or debA3A1–100. At 48 h, cells were starved and
radiolabeled with 35S-methionine/cysteine for 6 h. The medium was removed, cell lysates prepared in 1RIPA buffer and HA-tagged proteins immunoprecipitated with an
antibody against the HA-tag and protein A Sepharose. The proteins were resolved using SDS-PAGE and visualized by standard radiographic techniques. The lanes correspond
to the vector used to transfect 293 cells. Panels B–D. 293 cells were transfected with either the empty vector or plasmids expressing hA3A, colA3A, colA3A1–100, mndA3A1–
100, or debA3A1–100. At 24 h post-transfection, cells were transfected with plasmids with the HIV-1 genome. At 72 h, the culture supernatant were collected and assayed for
infectious virus using TZM-bl assays and p24 levels in culture supernatants and in cell lysates. Panel B. The level of infectious virus in the culture supernatants from
transfected cells using TZM.bl assays. Panel C. Levels of p24 antigen in the culture supernatants from transfected cells using commercially available p24 antigen capture kits.
Panel D. Levels of p24 antigen in the cell lysates from transfected cells using commercially available p24 antigen capture kits. The experiments in Panels B–D were performed
at least four times and statistical differences with the pcDNA3.1(þ)/HIV-1 control evaluated using a two-tailed Student's t-test, with po0.05 (Δ) considered signiﬁcant.
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Human A3A has been reported to edit nuclear and mitochon-
drial DNA and to induce the γH2AX (Landry et al., 2011; Suspène
et al., 2011a). Histone H2AX is a variant histone that represents
approximately 10% of the total H2A histone proteins in normal
human ﬁbroblasts. H2AX is required for checkpoint-mediated cell
cycle arrest and DNA repair following double-stranded DNA breaks
(Scully and Xie, 2013). DNA damage, caused by ionizing radiation,
UV-light, or radiomimetic agents, results in rapid phosphorylation
of H2AX at Ser139 by PI3K-like kinases, including ATM, ATR, and
DNA-PK (Redon et al., 2012). Monoubiquitination of H2AX induced
by RING ﬁnger protein 2 (RNF2) is also required for the recruit-
ment of active ataxia telangiectasia mutated (ATM) to DNA
damage foci and phosphorylation of H2AX at residue Ser139 to
generate γH2AX (Wu et al., 2011). Importantly, a defect in mono-
ubiquitination of H2AX profoundly enhances ionizing radiation
sensitivity. Of the seven hA3 proteins, the single cytidine deami-
nase domain hA3A, hA3C, and hA3H along with double deaminase
hA3B have been shown to have a nucleo-cytoplasmic localization
(Muckenfuss et al., 2006). A more recent study, however, demon-
strated that hA3A was not genotoxic to cells when expressed in
differentiated CD14þ cells and phorbol 12-myristate 13 acetate
treated THP-1 cells (Land et al., 2013). The discrepancy between
these results and that of Landry et al., 2011 could be due to the
differences between transfected and endogenous expression.
However, in the context of a gene-therapy approach, the possibi-
lity that hA3A could induce DNA damage responses following
exogenous expression is particularly important. Here, we found
that 293 cells expressing hA3A or colA3A led to the induction
of γH2AX and its mono-ubiquitinated form, although it was
consistently higher with hA3A. As the determinants for the
induction of γH2AX are unknown but presumably may be asso-
ciated with the zinc binding domain, and that colA3A restricted
HIV-1 by an apparently novel mechanism, we determined if
colA3A1–100 lost the ability to induce γH2AX expression. Our
results indicate that colA3A1–100 did not induce γH2AX over
background levels, indicating that expression of colA3A1–100
restricted HIV-1 replication without concomitant DNA damage
responses. Thus, further elucidation of the amino acid require-
ments of colA3A1–100 or mndA3A1–100 restriction of HIV-1 could
result in the use of these truncated proteins in HIV-1 gene therapy
approaches.
Materials and methods
Cells and viruses
293 cells were used for transfection of vectors expressing
various APOBEC3 proteins, full-length HIV-1 (NL4-3) or HIV-
1Δvif. The TZM-bl indicator cell line was used to measure the
infectivity of viruses (Derdeyn et al., 2000; Platt et al., 2009;
Takeuchi et al., 2008; Wei et al., 2002). Both cell lines were
maintained in Dulbecco's minimal essential medium (DMEM) with
10% fetal bovine serum (R10FBS), 10 mM Hepes buffer, pH 7.3, and
100 U/ml penicillin and 100 μg/ml streptomycin and 5 μg genta-
micin. A plasmid with the genome of HIV-1 strain NL4-3 (referred
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Fig. 10. A chimeric hA3A containing the AC Loop1 region of mndA3A restricts
HIV-1. 293 cells were grown to 50% conﬂuency and transfected with an empty
vector or vectors expressing hA3A, mndA3A, mnd25–34hA3A, or hA3G and and a
vector containing the HIV-1 genome. At 48 h, the culture supernatants were
collected and assayed for infectious virus using TZM-bl as an indicator cell line
or p24 levels in the culture supernatant and in cell lysates. Panel A. The level of
infectious virus in the culture supernatants from transfected cells using TZM.bl
assays. Panel B. Levels of p24 antigen in the culture supernatants from
transfected cells using commercially available p24 antigen capture kits. Panel
C. Levels of p24 antigen in the cell lysates from transfected cells using
commercially available p24 antigen capture kits. The experiments in Panels
A–C were performed three times and statistical differences with the pcDNA3.1
(þ)/HIV-1 control evaluated using a two-tailed Student's t-test, with po0.05
(Δ) considered signiﬁcant.
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to in the text as HIV-1; NIH AIDS Research and Reference Reagent
Program) and a Δvif version (referred to in text as HIV-1Δvif;
Schmitt et al., 2011) (pNL4-3; ) have been described.
Expression of colA3A in TZM-bl cells
TZM-bl cells in 6-well plates (50% conﬂuent) were trans-
fected with pcHA-colA3A (the colA3A gene with a HA-tag at the N-
terminus subcloned into the KpnI and EcoRV sites of pcDNA3.1(þ)
using ExGen500 reagent according to the manufacturers' instruc-
tions. At 48 h, the mediumwas removed and replaced with growth
medium containing 1 mg/ml of G-418. The cells were incubated
with the medium replaced every 3 days until non-transfected cells
were killed. Cells were then trypsinized, resuspended and diluted
such that single cells were seeded into each well of 96 well plate.
Cells were allowed to grow until they were conﬂuent, trypsinized
and seeded into 6 well plates and then into T-25 ﬂasks. Cultures
were examined for the expression of HA–colA3A using immuno-
precipitation analysis using an antibody against the HA-tag (Santa
Cruz Biotechnology). The TZM-bl cells were used for virus infec-
tivity assays.
Assessment of infectivity of Friend murine leukemia virus infectivity
in the presence of A3A proteins
One microgram of an infectious molecular clone of F-MuLV,
pLRB302, was co-transfected with 500 ng of A3A constructs into
293T cells using the Trans-IT reagent (MirusBio) (Li et al., 2013).
After 2 days, supernatants were collected and titered onto suscep-
tible Mus dunni cells using a focal infectivity assay as previously
described (Li et al., 2010). Cells were also harvested, lysed in RIPA
buffer and evaluated for A3A protein expression by loading 15 ug
protein into an SDS-PAGE gel and performing a western blot using
an anti-HA antibody (Roche). An antibody against beta-actin
(clone 8H10D10; Cell Signaling) was used to conﬁrm equal loading.
Assessment of reverse transcription in the presence of HA–colA3A
In order to assess the role of HA–colA3A on reverse transcrip-
tion, we generated pseudotyped NL4-3 pseudotyped virus with
the VSV-G protein. 293 cells in 12 well plates were co-transfected
with vector pNL4-3-deltaE-EGFP (2.4 μg), which has the env gene
replaced with the gene for GFP, and of vector pVSV-G (0.6 μg),
which expresses the VSV G protein using 8 μl of TurboFect
Transfection Reagent (Thermo Scientiﬁc). At 48 and 96 h, the
culture medium was harvested, centrifuged at 1200 g for
5 min, and the supernatants pooled and stored at 86 1C. The
infectious viral titers were determined using the TZM-bl cells. The
pseudotyped virus was designated as HIV-1ΔE-/VSV-G.
The levels of late reverse transcriptase products were quanti-
ﬁed using real time DNA PCR included 293 cells infected and the
following oligonucleotide primer set: U5-gag forward; LG564:
50-CCGTCTGTTGTGTGACTCTGGT-30; U5-gag reverse: LG699:
50-GAGTCCTGCGTCGAGAGATCT-30; U5-gag probe: LG-FAM: 50- FAM-
CCCGAACAGGGACTTGAAAGCGAA-TAMRA-30 (Suzuki et al., 2003).
Other controls for the experiment included the use of the reverse
transcriptase compound azidothymidine (AZT).
Assessment of integration in the presence of HA–colA3A
To determine if HA–colA3A interfered with viral genome
integration, we employed two different assays. The ﬁrst assay
detected the presence of 2-LTR circles, which occurs at a higher
frequency when integration is unsuccessful (Butler et al., 2001). To
quantify the levels of 2-LTR circles, 293 cells were transfected with
either the empty vector (pcDNA3.1(þ)) or the vector expressing
HA–colA3A. At 24 h, equal infectious units of HIV-1ΔE-/VSV-G
virus were then used to infect 293 cells for 48 h. Total cellular DNA
was puriﬁed using DNeasy Blood & Tissue Kit from Qiagen. The 2-
LTR circle levels were detected as previously described (Butler et
al., 2001). Real-time PCR was performed using the following
oligonucleotide primers:2-LTR circle forward, MH535: 50-AAC-
TAGGGAACCCACTGCTTAAG-30; 2-LTR circle reverse, ES2448 (based
on MH536):50-TCCACAGATCAAGGATCTCTTGTC-30; and 2-LTR
probe, MH603:50-(FAM)-ACACTACTTGAAGCACTCAAGGCAAGCTTT-
(TAMRA)-30. A standard curve of the ampliﬁcation being measured
was run ranging from 10 to 11011 copies. Reactions containing
1 premix (Takara), 0.5 μM forward primer, 0.5 μM reverse
primer, 0.25 μM probe and 1 RoxDyeII in a 20 μl volume. The
thermal cycle is 95 1C for 30 s, followed by 40 cycles of ampliﬁca-
tion at 5 s at 95 1C and 34 s at 60 1C.
In addition, we assessed the level of integration was by ampli-
ﬁcation Alu repeat/gag sequences. The oligonucleotides used for
detecting Alu-gag products were: (a) Alu-gag forward oligonucleo-
tide primer, MH535 (above); (b) Alu-gag reverse oligonucleotide
primer: SB704: 50-TGCTGGGATTACAGGCGTGAG-30. One microlitre
of sample from ﬁrst round regular PCR and subject to real-time
PCR with R/U5 primers (forward primer: M667-50GGCTAACTAG-
GGAACCCACTGC-30; reverse primer: AA55 -50CTGCTAGAGATT
TTCCACACTGAC-30) and probe (HIV FAM-50-TAGTGTGTGCCCG-
TCTGTTGTGTGAC-30TAM) (Suzuki et al., 2003). With each experi-
ment, a standard curve of the amplicon being measured was run in
duplicate ranging from 10 to 11011 copies plus a no-template
control. Reactions contained 1 premix (Takara), 0.5 μM forward
primer, 0.5 μM reverse primer, 0.25 μM probe primer and 100–
500 ng of template DNA and 1 RoxDyeII in a 20 μl volume. After
initial incubations of 95 1C for 30 s, 40 cycles of ampliﬁcation were
carried out at 5 s at 95 1C, 34 s at 60 1C. Reactions were analyzed
using the ABI Prism 7500 sequence detection system (PE-Applied
Biosystems, Foster City, California).
Construction of chimeric colobus/human A3A and truncated colA3A
proteins
As the hA3A protein and colA3A were phenotypically different
regarding restriction of HIV-1 in producer cells, we adopted to a
chimeric approach to determine if speciﬁc regions of the colA3A
protein were responsible for the inhibition of replication. We
γH2AX
γH2AX-Ub
A3A
β-actin WB: α-β-actin
WB: α-HA
WB: α-γH2AX
Fig. 11. Induction of γH2AX by hA3A and colA3A and colA3A1–100. 293 cells were
grown to 50% conﬂuency and cultures transfected with the empty vector pcDNA3.1
(þ) or vectors expressing hA3A, colA3A, or colA3A1–100. At 36 h, one half of the
cultures were treated with 20 μM etoposide (ETP) for 12 h and the remaining
cultures treated with DMSO. The cells were lysed and used in Western blots using
an antibody speciﬁc for γH2AX (Panel A), to the HA-tag to detect the A3A proteins
(Panel B) or β-actin (Panel C). The lanes correspond to the vector used to transfect
cultures of 293 cells and if they were treated with etoposide (ETP).
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generated a series of chimeric colobus/human A3A proteins, which
included col1–100hA3A (N-terminal 100 amino acids of colA3A
substituted for same region of hA3A), h1–100colA3A, col1–75hA3A,
col1–50hA3A and col1–33hA3A. All genes were synthesized with an
HA-tag at the N-terminus (Genscript) and subcloned into the
pcDNA3.1(þ) vector and sequenced to conﬁrm the integrity of
the gene. All lots of A3A plasmids were prepared in Escherichia coli
grown at 30 1C and each lot sequenced to insure no mutations
were introduced. The expression of each chimeric protein from
each plasmid was conﬁrmed by Western blot analysis before viral
replication assays were performed.
For construction of truncated colA3A, mndA3A and debA3A
proteins, sited-directed mutagenesis was use to introduce stop
codons after the N-terminal 100 amino acids (colA3A1–100,
mndA3A1–100, debA3A1–100). All genes were sequenced to insure
that only the desired mutations were introduced into the gene.
Immunoprecipitation of viral proteins
For analysis of A3A protein expression in cells, 293 cells in 6-
well plates were ﬁrst transfected with either pcDNA3.1(þ) or one
expressing each of the A3A proteins and incubated at 37 1C. At
48 h, the medium was removed and the cultures incubated in
medium without methionine/cysteine for 2 h and radiolabeled
with 300 μCi (per well) of 35S-methionine/cysteine for 6 h. The
medum was removed and the cells lysed in radioimmunoprecipi-
tation assay buffer (RIPA: 50 mM Tris–HCl, pH 7.5; 50 mM NaCl;
0.5% deoxycholate; 0.2% SDS; 10 mM EDTA) and HA-containing
proteins immunoprecipitated using a rabbit anti-HA antibody. The
immunoprecipitates were collected on Protein A Sepharose beads,
washed and boiled in sample reducing buffer. The proteins were
separated by SDS-PAGE and proteins visualized by standard auto-
radiographic techniques.
Immunoﬂuorescence studies of A3A localization
To examine the intracellular localization of HA–colA3A and the
truncated HA–colA3A1–100 proteins, 293 cells on cover slips were
transfected with empty vector, or vectors expressing HA–colA3A
or HA–colA3A1–100. At 48 h post-transfection, cells were washed
twice in cold PBS, and ﬁxed in 2% paraformaldehyde for 5 min at
room temperature. The cells were washed three times in cold PBS,
and incubated in a 0.5% Triton X-100 solution in PBS for 5 min.
Cells were once again washed with cold PBS and incubated with a
rabbit antibody against the HA-tag conjugated with Alexa488
prepared in PBS with 1% BSA for 1 h. The cells were then washed
three times with PBS, mounted and examined using a Leica TCS
SPE confocal microscope using a 63 objective using ﬁlters for
Alexa488 and DAPI.
Analysis of virus replication in the presence of A3A proteins
To analyze the virus restriction properties of the different A3A
proteins, chimeric colobus/human proteins and truncated A3A
proteins described above, 293 cells were ﬁrst transfected with a
vector expressing one of the A3A proteins and with a plasmid
containing the complete NL4-3 viral genome. At 48 h post-trans-
fection, the culture medium was collected, clariﬁed by low speed
centrifugation and analyzed for virus infectivity using TZM.bl cells.
All assays were performed with hA3A (non-restrictive); and
colA3A (restrictive). All assays were performed at least four times
and analyzed for statistical signiﬁcance using two-tiered Student's
t-test.
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